Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangxi Medical University
• Treatments: Capecitabine; Cyclophosphamide; Epirubicin; Fluorouracil

Criteria

Inclusion Criteria:

• Females aged 18-70 with histologically proven, core-biopsied, Stage II-III invasive breast cancer

• No distant disease

Exclusion Criteria:

• Inadequate heart or liver or kidney function